Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Lance Okeke

HIV/AIDS Medicine · Duke University

View

Dr. Raphael J. Landovitz

HIV/AIDS Medicine · UCLA

View

Dr. Aniruddha Hazra

HIV/AIDS Medicine · UCMC

View

Dr. Shital Patel

HIV/AIDS Medicine · BCM

View

Dr. Monica Gandhi

HIV/AIDS Medicine · UCSF

View

Dr. Ashwin Balagopal

HIV/AIDS Medicine · Johns Hopkins

View

Dr. Ofole Mgbako

HIV/AIDS Medicine · NYU Langone

View

Dr. Chris Beyrer

Global Health · Duke University

View

Dr. Keith Kaye

General ID · RU

View

Dr. Helen Boucher

Transplant/Immunocompromised States · Tufts

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    From Efficacy to Access in Long-Acting HIV Therapy

    Feb 26, 2026DOI: 10.1056/nejme2518334EditorialNEJM

    Written by: Joshua A. Barocas, M.D.

    Find these authors on Roon

    JB
    Dr. Joshua Barocas
    HIV/AIDS Medicine · CU Anschutz Medical Campus

    Summary

    Over the past three decades, advances in antiretroviral therapy (ART) have dramatically improved life expectancy, decreased frailty, and improved quality of life for persons with human immunodeficiency virus (HIV). These gains have accrued primarily among those who can reliably access health care and adhere to daily treatment. For many people who face structural and behavioral barriers to adherence, durable viral suppression remains elusive despite the availability of highly effective ART. Long-acting injectable ART offers the potential to extend the benefits of HIV treatment to populations in which adherence to daily oral ART has proved difficult. Although two phase 3 clinical trials . . .
    JBDr. Joshua Barocas
    Leading Voice

    Dr. Joshua Barocas

    Infectious Disease · HIV & AIDS Medicine
    University of Colorado Anschutz
    joshuab